cefixime reference
Reference image
(cefixime · DailyMed)
Registered Malawi · PMRA

CTAX T 200 200MG TABLET

CEFIXIME

PMPB/PL158/34 TABLET antiinfectives for systemic use INN generic

What it does

Cefixime is an antibiotic used to treat various bacterial infections.

Commonly used for: bacterial infections, urinary tract infections, gonorrhea

Read more in plain English ↓

Plain-language summary for general understanding - not medical advice. Always follow your pharmacist/doctor.

Ask about this medicine

Answers come only from this medicine's registration record, BNF monograph and interaction data - not medical advice.

Medicine sourcing is available in Kenya only. We don't sell or dispense medicines - licensed pharmacies do.

Sourcing - Kenya only

Registration & product details

Registration no.
PMPB/PL158/34
Registration date
31/01/2014
Expiry date
30/06/2017
Status
Registered
Active ingredient
CEFIXIME
Dosage form
TABLET
Strength
-
Pack size
-
Therapeutic class
-
ATC class (WHO)
J01DD - Third-generation cephalosporins
RxNorm RxCUI
25033
Manufacturer / MAH
-
Applicant / LTR
-
Country of origin
-

Source: Pharmacy and Medicines Regulatory Authority · fetched 2026-04-21 17:37:38 · updated 2026-09-15 04:32:43

Drug Interactions

3
Check interactions

Pharmacodynamic Warnings

Cefixime appears in TABLE 2: Drugs that cause nephrotoxicity

Unknown (3)

Cephalosporins - increases exposure

Leflunomideispredictedtoincreasetheexposureto cephalosporins(cefaclor).oTheoretical

Unknown Theoretical

Cephalosporins - increases exposure

Nitisinone is predicted to increase the exposure to cephalosporins (cefaclor).

Unknown Study

Cephalosporins - increases exposure

Teriflunomide is predicted to increase the exposure to cephalosporins (cefaclor).

Unknown Study

Data from BNF 85 (British National Formulary). This is not a substitute for professional medical advice. Matched via: class

Disclaimer: This information is sourced from Pharmacy and Medicines Regulatory Authority (Malawi). Always consult a qualified healthcare professional before using any medication.

About this medicine

Cefixime is an antibiotic used to treat various bacterial infections.

What it treats

  • bacterial infections
  • urinary tract infections
  • gonorrhea

How it works

Cefixime works by stopping the growth of bacteria, helping the body to fight off the infection.

Who it's for

Cefixime is for people with bacterial infections that can be treated with this type of antibiotic.

Drug class

Cephalosporins

Cautions

  • • Be cautious if taking other medications that can harm the kidneys.

AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.

Clinical monograph: Cefixime

BNF-referenced

Cefixime is a third-generation cephalosporin antibiotic, effective against a range of Gram-positive and Gram-negative bacterial infections. It works by inhibiting bacterial cell wall synthesis, leading to cell lysis. As a broad-spectrum antibiotic, cefixime is particularly useful in treating infections caused by bacteria that produce beta-lactamase enzymes, which typically confer resistance to other penicillins and cephalosporins.

Indications

  • Bacterial infections due to sensitive Gram-positive and Gram-negative bacteria
  • Surgical prophylaxis
  • Haemophilus influenzae epiglottitis
  • Acute infections
  • Meningitis (emergency treatment)
  • Uncomplicated gonorrhoea
  • Disseminated gonococcal infection

Dosage

Children: In children aged 1 month to 11 years

Adults: For adults, the typical dosage is 1 g every 12 hours for severe infections, or 400 mg for a single dose in cases of uncomplicated gonorrhoea.

Mechanism of action

Cefixime binds to penicillin-binding proteins (PBPs) located in the bacterial cell wall. This binding inhibits the transpeptidase activity essential for peptidoglycan cross-linking, thereby disrupting cell wall synthesis and integrity, which ultimately leads to bacterial cell lysis, especially in rapidly growing bacteria.

Pharmacodynamics

Cefixime exhibits bactericidal activity by preventing the final stages of bacterial cell wall synthesis. It is stable against certain beta-lactamases, making it effective against some resistant bacterial strains. The drug can cause hypersensitivity reactions and is associated with a risk of Clostridium difficile-associated diarrhea. It may also lead to a decrease in prothrombin activity, necessitating caution in susceptible populations.

Pharmacokinetics

Cefixime is well-absorbed after oral administration, with a bioavailability of approximately 40-50%. Peak plasma concentrations occur within 2-6 hours post-dose. It is widely distributed in body tissues and fluids, including urine. The drug is primarily eliminated via the kidneys, with dose adjustments required in patients with renal impairment. Cefixime has a half-life of about 3-4 hours, necessitating multiple doses for sustained therapeutic effect.

Contra-indications

  • Hypersensitivity to cefixime or other cephalosporins
  • Severe renal impairment

Adverse effects

  • Acute kidney injury
  • Arthralgia
  • Drug fever
  • Dyspepsia
  • Dyspnoea
  • Edema
  • Flatulence
  • Genital pruritus
  • Hypereosinophilia
  • Jaundice
  • Serum sickness-like reaction
  • Thrombocytosis

Interactions

  • Probenecid may increase cefixime levels
  • Cephalosporins may interact with anticoagulants and increase bleeding risk
  • Certain antibiotics may have additive effects

Precautions

  • Caution in patients with a history of gastrointestinal disease, particularly colitis
  • Monitor renal function in patients with renal impairment
  • Use with caution in patients on dialysis

Pregnancy

Not known to be harmful.

Breast-feeding

Present in milk in low concentrations; use with caution.

Storage

Store in a cool, dry place away from direct light. Keep out of reach of children.

Formulations

  • Oral tablets
  • Injection (intravenous and intramuscular)
BNF 85 (British National Formulary) p.599 BNF for Children 2019-2020 p.352 PubChem / pathway

AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.

Molecular reference: Cefixime

PubChem CID 5362065

Molecular formula: C16H15N5O7S2

Mechanism of action

The bacterial cell wall, which is located at the periphery of Gram-positive bacteria and within the periplasm of Gram-negative bacteria, comprises a glycopeptide polymer synthesized through cross-linking of glycans to peptide stems on alternating saccharides, which is known commonly as peptidoglycan. Cell wall formation, recycling, and remodelling require numerous enzymes, including a family of enzymes with similar active site character despite distinct and sometimes overlapping roles as carboxypeptidases, endopeptidases, transpeptidases, and transglycosylases, known as "penicillin-binding proteins" (PBPs). The number of PBPs differs between bacteria, in which some are considered essential and others redundant. In general, inhibition of one or more essential PBPs results in impaired cell wall homeostasis, loss of cell integrity, and is ultimately bactericidal. Cefixime is a cephalosporin and cephalosporins work by using their beta-lactam rings to inhibit bacterial cell wall synthesis by binding to the penicillin-binding proteins transpeptidases on bacteria. The inhibition of synthesis of the bacteria cell wall will cause lysis, particularly in fast growing organisms such as bacteria. Specifically, cephalosporins inhibit penicillin-sensitive enzymes responsible for the final 3D structure of the bacterial cell wall which in turn inhibit bacterial cell wall peptidoglycan synthesis.

Pharmacodynamics

Cefixime, a broad-spectrum antibiotic, is an orally-active third-generation semisynthetic cephalosporin. Like other cephalosporins, the antibacterial action of cefixime results from inhibition of cell wall synthesis. Also like other cephalosporins, cefixime is stable when in the presence of certain beta-lactamase enzymes, which means certain organisms resistant to penicillins and some cephalosporins due to the presence of beta-lactamases could be susceptible to cefixime. Use of cefixime can result in hypersensitivity reactions including anaphylactic/anaphylactoid reactions and _Clostridium difficile_-associated diarrhea (CDAD); it may also be associated with a fall in prothrombin activity. Cefixime doses should be adjusted for patients that have renal impairment and patients undergoing continuous ambulatory peritoneal dialysis (CAPD) and hemodialysis (HD), while patients on dialysis should be monitored while taking cefixime.

Source: PubChem (NCBI) · pathways from PathBank, Reactome, WikiPathways & PharmGKB.

This drug in other countries

The same active ingredient registered across other registries we cover - including different brands.